What's Going With WeightWatchers Stock On Wednesday?
What's Going With WeightWatchers Stock On Wednesday?
Over the past year, WeightWatchers has called local pharmacies across the country on behalf of members to conduct almost 3 million stock checks for GLP-1 medications and found them in stock just 4.5% of the time. These shortages can result in delays or interruptions of treatment.WeightWatchers (WW International) (NASDAQ:WW) stock is trading higher on Wednesday, with a session volume strong at 31.45 million, compared to an average volume of 3.25 million as per data from Benzinga Pro.
WeightWatchers（WW International）（納斯達克股票代碼：WW）股票週三上漲，交易日交易量強勁，爲3145萬，而Benzinga Pro的數據顯示，平均成交量爲325萬。
WeightWatchers stock is trading higher on continued strength after the company announced on Tuesday that it will add compounded semaglutide to its offering.
WeightWatchers週二宣佈將在其發行中增加複合索瑪魯肽後，該公司股價持續走高。
Semaglutide is an active ingredient in Novo Nordisk A/S's (NYSE:NVO) ultra popular Wegovy and Ozempic.
Semaglutide 是 Novo Nordisk A/S（紐約證券交易所代碼：NVO）超受歡迎的 Wegovy 和 Ozempic 中的一種活性成分。
Over the past year, WeightWatchers has called local pharmacies across the country on behalf of members to conduct almost 3 million stock checks for GLP-1 medications and found them in stock just 4.5% of the time. These shortages can result in delays or interruptions of treatment.
在過去的一年中，WeightWatchers代表會員致電全國各地的藥房，對近300萬個 GLP-1 藥物進行了庫存檢查，發現這些藥物的庫存量僅佔4.5％。這些短缺可能導致治療延遲或中斷。
Over the last six months, roughly 45% of WeightWatchers Clinic members eligible for and prescribed a GLP-1 by their clinician have been denied coverage by their insurance after three prior authorization requests.
在過去的六個月中，有資格接種 GLP-1 並由臨床醫生開處方的 WeightWatchers Clinic 會員中，大約 45% 在三次事先申請授權後被保險拒絕。
Less than 40% of insurers cover GLP-1 medications for weight loss, leaving many individuals living with obesity without crucial financial support. For those with coverage, more than half say their GLP-1 is still difficult to afford.
不到 40% 的保險公司承保用於減肥的 GLP-1 藥物，這使許多肥胖患者得不到重要的經濟支持。對於那些有保險的人，超過一半的人說他們的 GLP-1 仍然難以負擔得起。
WeightWatchers clinicians can prescribe compounded semaglutide if they determine that a GLP-1 weight-loss medication is appropriate for a patient.
如果 WeightWatchers 臨床醫生確定 GLP-1 減肥藥物適合患者，他們可以開復方索瑪魯肽的處方。
Eligible members can use their insurance for brand-name medications or choose to self-pay for brand-name medications or compounded semaglutide.
符合條件的會員可以使用保險購買名牌藥物，也可以選擇自費購買名牌藥物或複方索瑪魯肽。
Only patients meeting clinical eligibility requirements will be prescribed a compounded GLP-1; the clinical eligibility requirements for compounded GLP-1s are the same as for brand-name medications.
只有符合臨床資格要求的患者才能開復方 GLP-1 處方；複方 GLP-1 的臨床資格要求與名牌藥物的臨床資格要求相同。
If prescribed, WeightWatchers members receive their compounded semaglutide within 1-3 business days.
如果有處方，WeightWatchers會員將在1-3個工作日內收到複合索瑪魯肽。
The compounding groups Outsourcing Facilities Association and FarmaKeio Custom Compounding filed a complaint regarding the FDA's removal of Eli Lilly And Co's (NYSE:LLY) Tirzepatide from the shortage list.
複合組織外包設施協會和Farmakeio定製化合物就美國食品藥品管理局將禮來公司（紐約證券交易所代碼：LLY）的Tirzepatide從短缺清單中刪除提出了申訴。
The FDA's decision to withdraw the drug without prior notice or public consultation has been criticized for depriving patients of essential care, potentially driving up drug prices, and favoring special interests.
美國食品和藥物管理局在沒有事先通知或徵詢公衆意見的情況下撤回該藥的決定因剝奪患者基本護理、可能推高藥品價格和有利於特殊利益而受到批評。
Price Action: WW stock is up 50.01% at $1.73 during the premarket session at last check Wednesday.
價格走勢：在週三最後一次盤前交易中，WW股價上漲50.01％，至1.73美元。
- Newmont Strikes ~$1B Deal For Akyem Sale, Focus Sharpens on Tier 1 Assets
- 紐蒙特達成約10億美元的Akyem出售協議，重點關注一級資產
Image by Mohammed_Al_Ali via Shutterstock
圖片由 Mohammed_Al_Ali 通過 Shutterstock 拍攝
